Funded Tech Companies
Ancora Biotech
Headquartered in Palo Alto, Ancora Biotech has funding from SR One Capital Management and Lightspeed Venture Partners.
Company Overview
Company Name
Ancora Biotech
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
953 Roble Ridge Road
Palo Alto, CA 94306
CA
Palo Alto, CA 94306
CA
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
Ancora Biotech LLC is a privately held company supporting the clinical development of three multi-specific antibodies. These three antibodies are held in separate spin-offs, namely: 1) TeneoTwo holds our clinical stage TNB-486 (anti-CD19xCD3) T cell engager for the safe and effective treatment of B cell cancers, 2) TeneoFour holds our preclinical TNB-738 (anti-CD38) enzyme inhibitor for the treatment of inflammatory and metabolic disorders in the elderly, and 3) TeneoTen holds our preclinical T cell engager (anti-HBVxCD3) for the curative treatment of chronic hepatitis B infections (CHB). TNB-738 is poised to enter Phase I clinical studies by early 2022 and we anticipate to select a clinical lead for CHB by mid-2022.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
6/9/2022
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Roland Buelow
Chief Financial Officer
Stephen Dance
Chief Scientific Officer
Wim Schooten
Chief Technical Officer
Ute Schellenberger
Company Investors
- SR One Capital Management
- Lightspeed Venture Partners
Browse more funded tech companies:
Ancilia Biosciences | Ancora Heart
Share this article
About Our Venture Capital Database
The company data above is provided by VentureDeal.com, a leading supplier of venture capital funding data.
Additional Resources for Entrepreneurs